Although no specific delay threshold after diagnosis of breast cancer has been demonstrated to affect outcome, delays can cause anxiety, and surgical waiting time has been suggested as a quality measure. This study was performed to determine the interval from presentation to surgery in Medicare patients with nonmetastatic invasive breast cancer who did not receive neoadjuvant chemotherapy and factors associated with a longer time to surgery.
INTRODUCTION
Most published studies regarding delays focus on risks resulting from a delay in diagnosis of breast cancer, [1] [2] [3] suggesting that a delay is associated with lower disease-specific survival. 4 Paradoxically, current data do not demonstrate outcome differences from delays between diagnosis and surgery, 5, 6 and although it has been suggested that this interval has increased, 7 overall breast cancer outcomes continue to improve. [8] [9] [10] Because breast cancer diagnostic procedures are typically nontherapeutic, the interval of concern should theoretically encompass the entire time from presentation to treatment of the disease.
There is a current trend to establish quality improvement standards for breast cancer treatment. The length of an undue delay remains undefined, largely because there are little data comprehensively examining this entire interval, and no prospective trial can ethically subject patients to intentional delays to determine a threshold for harm. Defining appropriate times to surgery can also be problematic because of variability in evaluation, the extent of imaging required, preoperative medical clearance, second opinions, and the time that patients require to make a decision when a treatment choice exists. Nonetheless, a shorter preoperative interval may improve patient satisfaction 11 and lower anxiety.
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Although there is little correlation with outcomes, time to surgery has now been suggested as a possible measure for surgeons, [13] [14] [15] even though there are few national data regarding time to treatment of breast cancer in the United States encompassing the entire interval spanning presentation to surgery. Studies evaluating times to surgery for
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breast cancer are predominantly institutional and regional, 14, [16] [17] [18] with few reports exploring factors associated with greater preoperative delay.
5,11
On a national scale, 7, 19 the preoperative interval has only been characterized in limited fashion for association between delays and preoperative factors. 7, 20 Greater volumes of national data about treatment times for breast cancer exist for other countries, but the differences between health care systems may make such data irrelevant to the United States. This study was undertaken in the Medicare population to provide the first data detailing associations between evaluation components, surgery type, and interval length from the first physician appointment to the first therapeutic surgical procedure.
METHODS
Data were derived from the Surveillance, Epidemiology, and End Results (SEER) -Medicare linked claims database with approval from the National Cancer Institute. 21 This database matches SEER data with patient identifiers in the Medicare Master Enrollment File. 22 Patients were included if they were likely to have claims from 1 year before and after the SEER month of diagnosis. Exclusion criteria are listed in Figure 1 . All 16 applicable SEER registries were used to increase the external generalizability of the results. The SEER cancer diagnosis date is a clinical diagnosis date, specifying only a month and year. The interval between the first physician encounter and breast surgery was determined by searching from 1 year before to 1 year after the SEER diagnosis month. Patients having inconsistent or missing data were excluded. Although patients were restricted to their first breast cancer occurrence, those with a history of other malignancies were not excluded. Patients having preoperative radiotherapy or chemotherapy were excluded.
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Therapeutic intent was inferred by setting the therapeutic surgery date as that on which claims for one or more breast excision or mastectomy and one or more lymph node procedure were found, excluding patients having these performed on separate dates. Patients were defined as having a sentinel lymphadenectomy attempted or performed if a Medicare claim existed for sentinel node dye injection on that date and/or radionuclide injection on that date or up to 7 days prior.
Patients were classified as receiving breast-conserving surgery for claims including one or more local breast excision. Mastectomy patients included those having simultaneous local excisions. Bilaterality was not characterized because of difficulty distinguishing bilateral procedures from duplicate claims when modifiers were not reported.
The first clinician encounter was defined as the first visit having a breastrelated diagnosis code Յ 1 year before the SEER diagnosis date. These encounter dates and the definitive therapeutic surgery dates were established, defining the interval of interest. Thereafter, assessment within that interval was performed, excluding patients having neoadjuvant chemotherapy (defined by billing dates and codes). Although oral chemotherapeutic agents were not covered until 2006, chemotherapy claims are most accurate for agents used for breast cancer. 23 Imaging and procedures are enumerated by numbers of dates performed (eg, multiple mammographic studies on one patient on one date are counted as 1). Second breast cancers were characterized by the first day of their SEER month and year of diagnosis to establish diagnosis during their preoperative interval. Most data were derived from physician claims, supplemented by outpatient and inpatient hospital claims. All submitted Medicare claims were reviewed for relevant procedures and dates. If conflicts arose between Current Procedural Terminology codes and International Classification of Diseases Ninth Revision-Clinical Modification (ICD-9-CM) procedure codes, whose descriptions are less specific, Current Procedural Terminology data were preferentially used. If there were conflicts between physician and outpatient hospital claims, physician claims were used. The terms surgical delay and preoperative interval refer to the time interval from the first physician visit to first therapeutic surgery.
Because the preoperative interval distribution was highly skewed, median (quantile) regressions were used for analyses. 24 The bootstrap method with 1,000 repetitions was used for SEs. Charlson comorbidity index 25 was estimated from diagnosis codes using the method of Klabunde. 26, 27 The diagnosis year was included as a restricted cubic spline 28 to account for variation over the 1992 to 2005 period.
Adjusted median delays were computed using mean covariate values and parameters estimated in the multivariable models. Evaluation components were first detailed in four models, focusing separately on imaging, biopsies, clinician visits, and operative procedures, each including demographic/tumor variables. To explore the effect of time on delay and the relation to practice pattern changes, the interval increase was assessed, adjusting for factors in the models. Statistical significance was set at P ϭ .05 (two-sided). Analyses were performed using SAS software, version 9.2 (SAS Institute, Cary, NC), and STATA software, release 12 (StataCorp, College Station, TX).
RESULTS
Among patients developing invasive breast cancer after 1991 who were Ն 65 years old and who underwent cancer-directed surgery, 72,586 patients remained after exclusions (Fig 1) . Mean and median age were both 75 years, and median surgical delay was 29 days (interquartile [IQ] range, 15 to 51 days; mean, 56.5 days) with a mode of 15 days (n ϭ 1,955; 2.7%; Fig 2) . Overall median delay increased from 21 days in 1992 to 32 days in 2005. Breast-conserving surgery accounted for 23.4% of cancer-directed surgeries in 1992 (median delay, 22 days), increasing to 59.5% of surgeries in 2005 (median delay, 31 days). Delays for mastectomies began at 21 days in 1992, increasing to 34 days in 2005. In multivariable analysis, adjusted median surgical delay was notably greater for women (29 days v 24 days for men; P Ͻ .001; Table 1 ) and blacks and Hispanics (each 37 days v 28 days for whites; each P Ͻ .001).
The three most frequent diagnosis codes for the first physician encounter were consistent, irrespective of surgical delay. These were for a breast mass (ICD-9-CM: 611.72; 50.6%), malignant breast neoplasm, site unspecified (ICD-9-CM: 174.9; 12.5%), and abnormal breast findings (ICD-9-CM: 793.8; 6.5%; Appendix Table A1 , online only). Nearly 92% of patients had one evaluation/management claim on their initial encounter date (45.3% with surgeons, 17.7% with internists, 12.0% with family practitioners, and 5.6% with obstetrics/ gynecology). The other 8% had either multiple evaluation/management claims (6%) or were found only in outpatient claims where specialty code is not provided (2%).
After the initial physician encounter, a mean of three encounters occurred within the interval, including established patient, consultation, and new patient visits. A mean of two established patient visits and 1.1 new patient/consultation visits occurred.
For patients having biopsy claims of any type within the preoperative interval (n ϭ 50,830), median time from first visit to biopsy increased from 9 days (IQ range, 4 to 19 days) in 1992 to 13 days (IQ range, 6 to 30 days) in 2005 (P Ͻ .001), and median time from biopsy to surgery increased from 14 days (IQ range, 8 to 22 days) in 1992 to 22 days (IQ range, 14 to 34 days) in 2005 (P Ͻ .001). Except for multiple patient encounters, excisional biopsy added the greatest adjusted delay of any factor at 17 days, whereas reconstruction was associated with a 12-day adjusted added delay ( Table 2 ). A collapsed model adjusting for factors listed in Table 1 noted overall contributions to delay by imaging, biopsies, additional visits, and mastectomy (v breast conservation) of 10.4, 12.9, 10.8, and 0.6 days, respectively (all P Ͻ .001, except mastectomy: P ϭ .0012).
Mammography was identifiable in 67,751 patients (93.1%), including those performed during the preoperative interval and Յ 6 months before it, with 34,229 of these women (50.5%) having mammography before the first physician visit and 8,387 (12.4%) having mammography both before the visit and during the preoperative interval. Among 21,169 patients (31.2%) having mammography solely within the preoperative interval, median time from visit to mammogram was 4 days (mean, 12.3 days), and unadjusted median surgical delay was 34 days (mean, 47.5 days). If a mammogram was performed solely in the 6 months before the preoperative interval, the median unadjusted preoperative interval length was lower at 22 days (n ϭ 34,229; P Ͻ .001). Imaging and procedure codes are listed in Appendix Table A2 (online only) .
During the preoperative interval, 50,830 patients (70.0%) had biopsy claims, excluding image guidance claims without an associated biopsy code. Of these, 84.4% had one biopsy date, 13.5% had two biopsy dates, and 2.1% had Ն three biopsy dates. Among 3,858 patients (5.3%) who had a second breast cancer diagnosed with or after the index lesion, 52.3% of second breast cancers were found preoperatively and 25.8% (n ϭ 995) were found within the preoperative interval. Unadjusted surgical delays for common operative combinations are listed in Table 3 ; greater delays of up to 49 days were associated with longer reconstruction procedures.
Delay From First Encounter to Therapeutic Surgery (days) 
‫ء‬
Referent value for pairwise univariate comparisons. †Setting definitions are as follows: large metropolitan ϭ counties in metropolitan areas of Ն 1,000,000 population; metropolitan ϭ counties in metropolitan areas of Ͻ 250,000 to 1,000,000 population; urban ϭ urban population of Ն 20,000 adjacent or nonadjacent to a metropolitan area; less urban ϭ urban population of 2,500 to 19,999 adjacent or nonadjacent to a metropolitan area; and rural ϭ completely rural or Ͻ 2,500 urban population, adjacent or nonadjacent to a metropolitan area.
‡Region groupings are as follows: northeast ϭ Connecticut and New Jersey registries; south ϭ Atlanta, rural Georgia, Kentucky, and Louisiana registries; midwest ϭ Detroit and Iowa registries; and west ϭ Hawaii, New Mexico, Seattle, Utah, and California registries.
§Includes ipsilateral and contralateral breast. Table 2 elaborate adjusted added delays associated with each factor. The unadjusted surgical delay for all patients increased by 11 days between 1992 and 2005 (P Ͻ .001), dropping to a 5-day increase (P Ͻ .001) when adjusted for factors in Tables  1 and 2 .
Multivariable analyses in

DISCUSSION
In this study, we noted increases in the time to surgery overall and specific delays associated with imaging modalities, biopsy methods, Table 1 and the year of diagnosis. Associated delay refers to the coefficient, which is the time added to the preoperative interval that is associated with the factor in question. Abbreviations: CT, computed tomography; FNA, fine-needle aspiration; MRI, magnetic resonance imaging.
clinician visits, and operative procedures, irrespective of demographics, comorbidities, second breast cancers, and cancer stage. The specific contribution by each preoperative component has not previously been published to our knowledge, and our racial disparity findings provide specifics to previously noted delays. 19, 20 The data herein provide the first comprehensive preoperative delay information for components of the evaluation, which has been needed as greater consideration has been given to using time to surgery as a quality measure.
In this analysis, unlike in prior series, we felt that surgical waiting times must include analysis of the associated surgical procedures. We have found that breast cancer procedures have varied waiting times, probably because procedures must be scheduled into available operating room time, and longer procedures, those requiring coordination with other departments (such as nuclear medicine), and those involving coordination between surgeons may be more difficult to schedule. This is demonstrated by greater times for mastectomies, radionuclide use for sentinel node biopsy (v use of blue dye alone), and cases involving simultaneous reconstruction. These findings may enable individual institutions and surgeons to improve times to surgery by predicting the impact of these components and assessing their times relative to the country for the common procedures delineated in Table  3 . Despite accounting for metropolitan setting and US region, we found that racial disparities for time to surgery remained, although whether these are a result of financial, prejudicial, cultural, or other factors remains unknown. It must also be recognized that a statistically significant difference in delay may be different than a clinically significant one. Until outcomes data support a specific problematic threshold, the reader must make a judgment about whether the delays seen here are clinically meaningful.
There is less available data on waiting times to surgery in the United States than there is for Canada and the United Kingdom. In a series from Ontario evaluating the practices of 62 surgeons in eight cancer centers, breast and other cancer types were combined. 29 Median time from first visit to treatment decision was 0 days, median time from treatment decision to surgery was 20 days, and median time from referral to surgery was 37 days. In the United Kingdom, treatment times varied once a 2-week waiting rule for patients with breast cancer was implemented. 30 In the United Kingdom and Canada, breast cancer survival is slightly lower than in the United States, 31 although it remains unknown whether this is associated with preoperative delay or other factors. 32, 33 In the most comprehensive US study to date, analysis of Commission on Cancer hospitals composing the National Cancer Data Base (NCDB) demonstrated that cancer surgery waiting times have increased for all cancer sites evaluated, including breast, between 1995 and 2005. 7 This NCDB study did not evaluate surgical specifics, but like their overall increase in time to surgery, we found delays increasing from 21 days in 1992 to 32 days in 2005, with similar trends for breast conservation and mastectomies. Although our study was unable to determine whether a single institution performed evaluation and treatment, the NCDB study noted a median waiting time from diagnosis to treatment of 22 days when performed at the same institution versus 26 days if performed at different hospitals. We noted a greater delay associated with increasing numbers of physician visits. These may include plastic surgery or other specialists, second opinions, or transfers of care, consistent with those NCDB findings. Although clinician specialty at presentation theoretically may also be associated with different delays, neither our study nor the NCDB study evaluated this. Instead, we felt that the number of clinician visits was more pertinent than specialty and better reflected practice patterns, which may vary widely even within specialty.
Curiously, we noted a sawtooth pattern in the time to surgery consisting of 3-day spikes, each centered at regular 7-day intervals (Fig  2) . Fedewa et al 20, 34 plotted similar sawtooth patterns in two studies evaluating times to any first treatment in minorities 20 and to postoperative chemotherapy, 34 although they did not comment on the shapes of their histograms. We believe that this consistent finding demonstrates a real pattern of care in waiting times nationwide and is related to specific days of the week when clinic or operating room and radiotherapy up to 20 weeks. 37, 38 Such studies must be retrospective, as ethics prohibits prospectively subjecting patients to intentional delay to assess consequent harm, and it behooves the clinician to provide as timely care as feasible. Still, some systems such as the United Kingdom's National Health System are also now considering abandoning measured performance targets for patient waiting times, 39 presumably because of practical considerations.
The rate of increase in time to surgery seen here was lessened by adjusting for the demographic and preoperative evaluation components assessed. This suggests that a change in practice patterns may be contributing to that increasing delay. Whether this represents changes in breast cancer presentation or greater numbers of episodes of care (ie, visits, biopsies, imaging, and so on) remains uncertain, but with a growing patient population, any defined acceptable preoperative interval length may become increasingly difficult to achieve. More episodes of care may cause delay but may allow for better assessment of treatment alternatives, because there have been changes in treatment standards over time associated with improvements in outcomes.
10,40-42 The paradox of increasing surgical delay during such improvements suggests that the effect of small preoperative delays should not be overstated, and the association of defined delays with each preoperative component may demonstrate that some delays are unavoidable. Although delay may be associated with anxiety, the delays associated with evaluation components are short. Excisional biopsy demonstrated the largest adjusted delay, adding 17 days, but this is no longer standard of care for diagnosis, 43 and it is unlikely that even this would affect outcomes.
It must be recognized that the supply of clinicians or other resources may also affect delay, and we could not assess some factors that undoubtedly contributed, such as patient decision-making time and the scheduling challenges of the patient and clinician. We also noted that only 70% of patients had identifiable biopsy claims in the preoperative interval. This may reflect image guidance claims billed without the biopsy codes, biopsies performed before the first clinician visit, and excisional biopsies performed at the therapeutic surgery. Additionally, the short delay associated with breast magnetic resonance imaging (MRI) relative to ultrasound and mammography was also surprising (Table 1) in light of prior data reported by us  44 and others   11,16,45 noting a greater interval difference with breast MRI in the routine preoperative setting. Breast MRI was only performed in 2% of these patients, however, and their indications remain unknown. Ductograms, positron emission tomography scans, and brain MRIs, each performed in less than 1% of patients, were not included because of their rarity. We predicted that procedural bilaterality may also affect waiting times and attempted to assess this, but we had concerns about accuracy. This was also highly correlated with second cancers, which were included in our models. We also noted a low number of reconstruction claims, although this may be reflective of delayed reconstruction, cohort age, or period of study because reconstruction use has increased over time.
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Despite potential limitations, the SEER-Medicare data set has been demonstrated to be accurate for several aspects of care, 22,23,47 and although these trends and associations cannot be assumed to be generalizable to the commercially insured or uninsured US population, the highest breast cancer age-specific incidence rates for men and women occur in those older than 65 years, who are eligible for Medicare. 48 As patient numbers grow and resources become fewer, increasing delays may require periodic assessment to ensure that there is no detrimental effect on breast cancer outcomes.
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